Search Results for "Alcar Insulin"

06:41 EDT 20th October 2017 | BioPortfolio

Original Source: Acetyl-L-Carnitine in Type 2 Diabetes

Decreased insulin sensitivity (or insulin resistance) is a major risk factor for type 2 diabetes mellitus and renal and cardiovascular disease. It is the key component and, possibly, a pathogenetic factor of the metabolic syndrome - a clustering of arterial hypertension, obesity, impaired glucose tolerance, dyslipidemia, coagulation abnormalities, albuminuria and increased cardiovascular risk - that may preceed or accompany type 2 diabetes. Insulin function and the abno...

Matching Channels

Matching News

CARMAT appoints Francesco Arecchi, previously Product Manager EMEA Structural Heart at Abbott, as Marketing Manager

Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, aiming to provide a therapeutic alternative for...

As insulin prices rise, endocrinologists confront growing crisis

The number of Americans with diabetes continues to grow, along with the need for insulin therapy. Between 1997 and 2011, the age-adjusted percentage of adults with diagnosed diabetes prescribed both i...

Biosimilars of insulin lispro

Last update: 18 August 2017Insulin glargine is a fast acting insulin analogue used to treat people living with Type 1 or Type 2 diabetes. Insulin lispro has one primary advantage over regula...

Insulin Pump Superior to Insulin Injection for Type 1 Diabetes Mellitus

Insulin pump therapy was associated with lower rates of severe hypoglycemia and ketoacidosis and better glycemic control compared with insulin injection therapy in a pediatric population.

Comparing Insulin Treatments for Diabetic Patients

Authors of two studies suggested that 32 weeks’ treatment with insulin degludec vs. insulin glargine U100 resulted in a reduced rate of overall symptomatic hypoglycemic episodes.

Pivotal study begins for algorithm-enhanced insulin pump

Medical device firm Tandem Diabetes is to trial a new algorithm-based version of its leading insulin pump which can predict future blood glucose levels and automatically adjust insulin levels accordin...

Effective Use of Human Insulin in Type 2 Diabetes

This Viewpoint suggests that clinicians prescribe human insulin products as a more-affordable option over insulin analogues and explains dosing options.

FDA Clears New Insulin-Dosing Software System

Automated insulin adjustment is a rapidly growing "hot spot" for diabetes technology; algorithm assists in optimizing both basal and bolus insulin dosing. News Alerts

Matching PubMed Articles

ALCAR promote adult hippocampal neurogenesis by regulating cell-survival and cell death-related signals in rat model of Parkinson's disease like-phenotypes.

Parkinson's disease (PD) is characterized by the degeneration of dopaminergic neurons in the nigrostriatal pathway that leading to progressive motor and nonmotor symptoms. The formation of newborn neu...

Serum insulin bioassay reflects insulin sensitivity and requirements in type 1 diabetes.

Insulin resistance could increase insulin requirements in type 1 diabetes (TD1). Current insulin immunoassays do not detect insulin analogues. Kinase Insulin Receptor Activation (KIRA) bioassays speci...

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/ml vs. insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring (CGM): a randomized crossover study.

We compared the effects of morning administration of insulin glulisine + insulin glargine 300 U/ml (G+G300) to that of insulin lispro + insulin glargine biosimilar (L+GB).

Neuroprotective Effects of Acetyl-L-Carnitine on Neonatal Hypoxia Ischemia-Induced Brain Injury in Rats.

Perinatal hypoxia ischemia (HI) is a significant cause of brain injury in surviving infants. Although hypothermia improves outcomes in some infants, additional therapies are needed since about 40% of ...

Internalization and localization of basal insulin peglispro in cells.

Basal insulin peglispro (BIL) is a novel, PEGylated insulin lispro that has a large hydrodynamic size compared with insulin lispro. It has a prolonged duration of action, which is related to a delay i...

Search Whole site using Google

Quick Search
Advertisement Advertisement